DelveInsight’s, “Coccidioidomycosis Pipeline Insight 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Coccidioidomycosis pipeline landscape. It covers the Coccidioidomycosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Coccidioidomycosis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Coccidioidomycosis Pipeline? Click here to explore the therapies and trials making headlines @ Coccidioidomycosis Pipeline Outlook Report

Key Takeaways from the Coccidioidomycosis Pipeline Report

• DelveInsight’s Coccidioidomycosis Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Coccidioidomycosis treatment.
• The leading Coccidioidomycosis Companies such as SCYNEXIS, Mycovia Pharmaceuticals, Amplyx Pharmaceuticals, F2G and others.
• Promising Coccidioidomycosis Therapies such as Posaconazole, Fluconazole, Olorofim, Ibrexafungerp and others.

Want to know which companies are leading innovation in Coccidioidomycosis? Dive into the full pipeline insights @ Coccidioidomycosis Clinical Trials Assessment

The Coccidioidomycosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Coccidioidomycosis Pipeline Report also highlights the unmet needs with respect to the Coccidioidomycosis.

Coccidioidomycosis Overview

Coccidioidomycosis is caused by Coccidioides immitis, a soil fungus native to the San Joaquin Valley of California, and by C posadasii, which is endemic to certain arid-to-semiarid areas of the southwestern United States, northern portions of Mexico, and scattered areas in Central America and South America. Although genetically distinct, the 2 species are morphologically identical. Coccidioidomycosis is typically transmitted by inhalation of airborne spores of C immitis or C posadasii. Infection occurs in endemic areas and is most commonly acquired in the summer or the late fall during outdoor activities.

Coccidioidomycosis Emerging Drugs Profile

• Ibrexafungerp: SCYNEXIS

Ibrexafungerp (formerly SCY-078) is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. It has shown activity against Aspergillus and Candida, including against multidrug-resistant (MDR) species Candida auris as well as Pneumocystis. Ibrexafungerp combines the well-established activity of glucan synthase inhibitors with the flexibility of oral and IV formulations, offering a broad use across different settings (in-patient and out-patient).

• VT-1598: Mycovia Pharmaceuticals

Mycovia is currently evaluating VT-1598, an oral antifungal, in Phase 1 clinical trials, for the treatment of serious fungal pathogens that pose a growing global threat due to underlying multidrug resistance. VT-1598 has QIDP designation, Fast Track status, and orphan designation for Valley fever (coccidioides); cryptococcal meningitis is eligible for FDA’s priority review voucher program.

If you’re tracking ongoing Coccidioidomycosis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Coccidioidomycosis Treatment Drugs

The Coccidioidomycosis Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Coccidioidomycosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Coccidioidomycosis Treatment.
• Coccidioidomycosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Coccidioidomycosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Coccidioidomycosis market.

Coccidioidomycosis Companies

SCYNEXIS, Mycovia Pharmaceuticals, Amplyx Pharmaceuticals, F2G and others.

Coccidioidomycosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Coccidioidomycosis Products have been categorized under various Molecule types such as,

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

From emerging drug candidates to competitive intelligence, the Coccidioidomycosis Pipeline Report covers it all – check it out now @ Coccidioidomycosis Market Drivers and Barriers, and Future Perspectives

Scope of the Coccidioidomycosis Pipeline Report

• Coverage- Global
• Coccidioidomycosis Companies- SCYNEXIS, Mycovia Pharmaceuticals, Amplyx Pharmaceuticals, F2G and others.
• Promising Coccidioidomycosis Therapies- Posaconazole, Fluconazole, Olorofim, Ibrexafungerp and others.
• Coccidioidomycosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Coccidioidomycosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Coccidioidomycosis Treatment landscape in this detailed analysis @ Coccidioidomycosis Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Coccidioidomycosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Coccidioidomycosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Ibrexafungerp: SCYNEXIS
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. VT-1598: Mycovia Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Coccidioidomycosis Key Companies
21. Coccidioidomycosis Key Products
22. Coccidioidomycosis- Unmet Needs
23. Coccidioidomycosis- Market Drivers and Barriers
24. Coccidioidomycosis- Future Perspectives and Conclusion
25. Coccidioidomycosis Analyst Views
26. Coccidioidomycosis Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/coccidioidomycosis-pipeline-insight